Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Condylomata Acuminata 2Warts 1High-grade Anal Intraepithelial Neoplasia 1Carcinoma, Basal Cell 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Vaccines, Synthetic 7Papillomavirus Vaccines 6Vaccines 3Imiquimod 3Gels 3green tea extract polyphenone E 2Trichloroacetic Acid 2Duration of Therapy 2Cantharidin 2ranpirnase 1polyphenon E 1nanocurcumin 1human papillomavirus vaccine, L1 type 16, 18 1berdazimer sodium 1Viusid 1VP-102 1Therapies, Investigational 1Tea 1Surgical Procedures, Operative 1Omiganan 1Ointments 1Medical Records 1Interleukin-4 1Human Papillomavirus Recombinant Vaccine nonavalent 1Hepatitis B Vaccines 1GS-9191 1Ethanol 1Cyclophosphamide 1Curcumin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Condylomata Acuminata × green tea extract polyphenone E × Clear all
NCT01490008 2012-04-19

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

MediGene

Phase 1 Completed
30 enrolled

Condylomata Acuminata

NCT01082302 2010-09-08

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

MediGene

Phase 4 Completed
43 enrolled

Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡